These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 25862847)

  • 1. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
    Aderhold C; Faber A; Umbreit C; Birk R; Weiss C; Sommer JU; Hörmann K; Schultz JD
    Anticancer Res; 2015 Apr; 35(4):1951-9. PubMed ID: 25862847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecules alter VEGFR and PTEN expression in HPV-positive and -negative SCC: new hope for targeted-therapy.
    Aderhold C; Faber A; Umbreit C; Chakraborty A; Bockmayer A; Birk R; Sommer JU; Hörmann K; Schultz JD
    Anticancer Res; 2015 Mar; 35(3):1389-99. PubMed ID: 25750290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule-based chemotherapeutic approach in p16-positive and -negative HNSCC in vitro.
    Aderhold C; Faber A; Grobschmidt GM; Chakraborty A; Bockmayer A; Umbreit C; Birk R; Stern-Straeter J; Hörmann K; Schultz JD
    Anticancer Res; 2013 Dec; 33(12):5385-93. PubMed ID: 24324073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGF Expression in HPV16-positive and -negative SCC After Treatment With Small-molecule Tyrosine Kinase Inhibitors and Everolimus.
    Huber L; Birk R; Knuettel M; Rotter N; Aderhold C; Scherl C; Lammert A; Jungbauer F; Kramer B
    Anticancer Res; 2020 Oct; 40(10):5621-5630. PubMed ID: 32988886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
    Schultz JD; Mühlheim K; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
    Oncol Rep; 2011 Nov; 26(5):1099-109. PubMed ID: 21805039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines.
    Affolter A; Samosny G; Heimes AS; Schneider J; Weichert W; Stenzinger A; Sommer K; Jensen A; Mayer A; Brenner W; Mann WJ; Brieger J
    Head Neck; 2017 Apr; 39(4):623-632. PubMed ID: 28221700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
    Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinase-2 and -14 in p16-positive and -negative HNSCC after exposure To 5-FU and docetaxel In Vitro.
    Aderhold C; Umbreit C; Faber A; Birk R; Sommer JU; Hörmann K; Schultz JD
    Anticancer Res; 2014 Sep; 34(9):4929-37. PubMed ID: 25202075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Therapies in HPV-positive and -negative HNSCC - Alteration of EGFR and VEGFR-2 Expression In Vitro.
    Kramer B; Hock C; Birk R; Sauter A; Stuck BA; Hörmann K; Schultz JD; Aderhold C
    Anticancer Res; 2016 Jun; 36(6):2799-807. PubMed ID: 27272791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
    Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
    Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis.
    Maute L; Grünwald V; Weikert S; Kube U; Gauler T; Kahl C; Burkholder I; Bergmann L
    J Cancer Res Clin Oncol; 2014 May; 140(5):823-7. PubMed ID: 24556802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI.
    Park K; Lee JL; Park I; Park S; Ahn Y; Ahn JH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Med Oncol; 2012 Dec; 29(5):3291-7. PubMed ID: 22460837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
    Aderhold C; Umbreit C; Faber A; Sauter A; Sommer JU; Birk R; Erben P; Hofheinz RD; Stern-Straeter J; Hörmann K; Schultz JD
    Anticancer Res; 2013 May; 33(5):1951-61. PubMed ID: 23645743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer.
    Paglino C; Procopio G; Sabbatini R; Bellmunt J; Schmidinger M; Bearz A; Bamias A; Melichar B; Imarisio I; Tinelli C; Porta C
    Anticancer Res; 2013 Nov; 33(11):4999-5004. PubMed ID: 24222142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unexpected alteration of β-catenin and c-KIT expression by 5-FU and docetaxel in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
    Umbreit C; Aderhold C; Faber A; Sommer JU; Sauter A; Hofheinz RD; Stern-Sträter J; Hoermann K; Schultz JD
    Anticancer Res; 2013 Jun; 33(6):2457-65. PubMed ID: 23749896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib-associated matrix metalloproteinase suppression in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
    Umbreit C; Aderhold C; Faber A; Sauter A; Hofheinz RD; Stern-Straeter J; Hoermann K; Schultz JD
    Oncol Rep; 2014 Aug; 32(2):668-76. PubMed ID: 24890748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer.
    Rosa R; Damiano V; Nappi L; Formisano L; Massari F; Scarpa A; Martignoni G; Bianco R; Tortora G
    Br J Cancer; 2013 Aug; 109(3):686-93. PubMed ID: 23839492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies].
    Siebels M; Hegele A; Varga Z; Oberneder R; Doehn C; Heinzer H;
    Urologe A; 2011 Sep; 50(9):1110-7. PubMed ID: 21559917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapeutic alteration of β-catenin and c-kit expression by imatinib in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
    Schultz JD; Sommer JU; Hoedt S; Erben P; Hofheinz RD; Faber A; Thorn C; Hörmann K; Sauter A
    Oncol Rep; 2012 Jan; 27(1):270-80. PubMed ID: 21993766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of Tyrosine Kinase Inhibitors and Everolimus on TGFβ1 and TGF-β Receptor 2 in Squamous Cell Carcinoma Cells.
    Huber L; Knüttel MT; Kramer B; Zaubitzer L; Lammert A; Scherl C; Rotter N; Häussler D
    Anticancer Res; 2024 Aug; 44(8):3287-3294. PubMed ID: 39060052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.